Dataset Information

Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility.

ABSTRACT: OBJECTIVE:To evaluate the completeness and accessibility of public information about US clinical trials of drugs in development. DESIGN:Review of online registers of clinical trials. DATA SOURCES:Drugs in phase III trials were identified using three drug industry sources: PhRMA Survey, What's in the Pipeline, and the NDA Pipeline. Drug trials were then searched for on the following publicly accessible registers of clinical trials:, and registers associated with the 37 "Comprehensive Cancer Centers" designated by the National Cancer Institute. MAIN OUTCOME MEASURE:Extent of availability of public information on phase III trials of drugs in development for treating either prostate or colon cancer. RESULTS:Search of industry sources identified 12 drugs for prostate cancer and 20 for colon cancer undergoing phase III trials. The most comprehensive publicly available register, contained trial listings for only seven of the prostate cancer drugs and 10 of the colon cancer drugs. Trials of three prostate cancer and three colon cancer drugs were listed on only one register each. A substantial proportion of trials of prostate cancer drugs (3/12) and colon cancer drugs (8/20) were not associated with trial listings in any registers. CONCLUSIONS:Existing trials registers are unlikely to be meeting user needs since many ongoing drug trials are not listed. There is a clear need for a comprehensive clinical trials register encompassing all ongoing trials, including industry sponsored trials.

SUBMITTER: Manheimer E

PROVIDER: S-EPMC124135 | biostudies-literature | 2002 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility.

Manheimer Eric E Anderson Diana D

BMJ (Clinical research ed.) 20020901 7363

<h4>Objective</h4>To evaluate the completeness and accessibility of public information about US clinical trials of drugs in development.<h4>Design</h4>Review of online registers of clinical trials.<h4>Data sources</h4>Drugs in phase III trials were identified using three drug industry sources: PhRMA Survey, What's in the Pipeline, and the NDA Pipeline. Drug trials were then searched for on the following publicly accessible registers of clinical trials:, and registers associated with the 37 "Comp ...[more]

PMID: 12217994

Similar Datasets

Project description:ObjectivesConduct a head-to-head experimental test of responses to alcohol harm reduction advertisements developed by alcohol industry Social Aspects/Public Relations Organisations (SAPROs) versus those developed by public health (PH) agencies. We hypothesised that, on average, SAPRO advertisements would be less effective at generating motivation (H1) and intentions to reduce alcohol consumption (H2) but more effective at generating positive perceptions of people who drink (H3).DesignOnline experiment with random assignment to condition.Participants2923 Australian adult weekly drinkers (49% high-risk drinkers) recruited from an opt-in online panel.InterventionsParticipants viewed 3 of 83 advertisements developed by PH agencies (n=2174) or 3 of 28 advertisements developed by SAPROs (n=749).Primary outcome measuresParticipants reported their motivation to reduce the amount of alcohol consumed; behave responsibly and/or not get drunk; and limit their drinking around/never supply to minors, as well as intentions to avoid drinking alcohol completely; reduce the number of drinking occasions; and reduce the amount of alcohol consumed per occasion. Participants also reported their perceptions of people who drink alcohol on six success-related items and four fun-related items.ResultsCompared with drinkers exposed to PH advertisements, those exposed to SAPRO advertisements reported lower motivation to reduce the amount of alcohol consumed (β=-0.091, 95% CI -0.171 to -0.010), and lower odds of intending to avoid alcohol completely (OR=0.77, 0.63 to 0.94) and to reduce the amount of alcohol consumed per occasion (OR=0.82, 0.69 to 0.97). SAPRO advertisements generated more favourable fun-related perceptions of drinkers (β=0.095, 0.013 to 0.177).ConclusionsThe alcohol harm reduction advertisements produced by alcohol industry SAPROs that were tested in this study were not as effective at generating motivation and intentions to reduce alcohol consumption as those developed by PH organisations. These findings raise questions as to whether SAPROs should play a role in alcohol harm reduction efforts.

Project description: To investigate the practice of post-marketing studies in Germany during a three year period and to evaluate whether these trials meet the aims specified in the German Medicinal Products Act. Survey of notifications submitted to German regulatory agencies before post-marketing studies were carried out, 2008-10. Notifications obtained through freedom of information requests to the three authorities responsible for registering post-marketing studies in Germany. Descriptive statistics of post-marketing studies, including the products under study, intended number of patients, intended number of participating physicians, proposed remunerations, study plan and protocol, and availability of associated scientific publications and reports on adverse drug reactions. Information was obtained from 558 studies, with a median of 600 (mean 2331, range 2-75?000) patients and 63 (270, 0-7000) participating physicians per study. The median remuneration to physicians per patient was €200 (€441, €0-€7280) (£170, £0-£6200; $215, $0-$7820), with a total remuneration cost of more than €217m for 558 studies registered over the three year period. The median remuneration per participating physician per study was €2000 (mean €19?424), ranging from €0 to €2?080?000. There was a broad range of drugs and non-drug products, of which only a third represented recently approved drugs. In many notifications, data, information, and results were, by contract, strictly confidential and the sole property of the respective sponsor. No single adverse drug reaction report could be identified from any of the 558 post-marketing studies. Less than 1% of studies could be verified as published in scientific journals. Post-marketing studies are not improving drug safety surveillance. Sample sizes are generally too small to allow the detection of rare adverse drug reactions, and many participating physicians are strictly obliged to maintain confidentiality towards the sponsor. High remuneration and strict confidentiality clauses in these studies could influence the physicians' reporting behaviours of adverse drug reactions.

Project description:BackgroundOpinions and practices vary around the issue of performing multiple statistical tests in randomised controlled trials (RCTs). We carried out a study to collate information about opinions and practices using a methodological rapid review and a survey, specifically of publicly funded pragmatic RCTs that are not seeking marketing authorisation. The aim was to identify the circumstances under which researchers would make a statistical adjustment for multiplicity.MethodsA review was performed extracting information from articles reporting primary analyses of pragmatic RCTs in one of seven high quality medical journals, in January to June (inclusive) 2018. A survey (Survey Monkey) eliciting opinions and practices around multiplicity was distributed to the 47 registered clinical trials units (CTUs) in the UK.ResultsOne hundred and thirty-eight RCTs were included in the review, and survey responses were received from 27/47 (57%) CTUs. Both the review and survey indicated that adjusting for multiplicity was considered most important for multiple treatment comparisons; adjustment was performed for 11/23 (48%) published trials, and 24/27 (89%) CTU statisticians reported they would consider adjustment. Opinions and practices varied around adjustment for multiplicity arising from multiple primary outcomes and interim analyses. Adjustment was considered less important for multiplicity due to multiple secondary outcomes (adjustment performed for 17/136 [13%] published trials and 3/27 [11%] CTU statisticians would consider adjustment) and subgroup analyses (8/85 [9%] published trials adjusted and 6/27 CTU [22%] statisticians would consider adjustment).ConclusionsThere is variation in opinions about adjustment for multiplicity among both statisticians reporting RCTs and applied statisticians working in CTUs. Further guidance is needed on the circumstances in which adjustment should be considered in relation to primary trial hypotheses, and if there are any situations in which adjustment would be recommended in the context of secondary analyses.

Project description:This article presents data collected using online surveys conducted in Norway, Tasmania (Australia) and Iceland, with the aim of exploring public perceptions of the salmon aquaculture industry in each country. A total of 2085 survey participants provided responses, with 1183 from Norway, 406 from Tasmania, and 496 from Iceland. The survey encompassed various aspects of attitudes towards and perceptions of the aquaculture industry. Participants were asked questions regarding their environmental concerns, trust in governance and management, and knowledge of the aquaculture industry in their respective country. Additionally, attitudes towards the industry were explored using questions related to preferences regarding information sources, perceptions of industry contributions, distribution of economic benefits, financial significance in local community, sustainability, and acceptance and tolerance of industry production. Respondents were also given the opportunity to provided text comments regarding the areas in which they thought the industry should become more sustainable. Demographic data on the respondents were collected, directly from the participants and from existing panel data from the survey company. However, the dataset excludes information on residence on the local level (postal code) to ensure anonymity of the respondents. The survey design was created by the SoLic-project (2019-2022, supported by the Research Council of Norway, no. 295114), drawing on the social license literature and the team's extensive research experience on topics related to the aquaculture industry, social acceptance, and legitimacy. The dataset presented in the article combines raw survey data with additional analysis data derived from grouping answer options or recoding data variables. The data provided in this article offers a valuable resource for researchers, industry representatives, public authorities, and other parties interested in salmon aquaculture. It enables comparative analyses and further investigations into public perceptions in Norway, Tasmania, and Iceland. This dataset can be used to explore a wide range of topics and extend the research conducted by the SoLic project team.

Dataset Information

Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility.

Publications

Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets